A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

July 29, 2020

Study Completion Date

July 29, 2020

Conditions
Healthy AdultsSkin Enhancement
Interventions
DEVICE

Juvederm® VOLITE

1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).

Trial Locations (1)

80288

EuroFins Dermscan Poland, Gdansk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT04206293 - A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers | Biotech Hunter | Biotech Hunter